- Home
- GORO vs CVM Comparison
GORO vs CVM Comparison
Compare GORO & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORO
- CVM
- Stock Information
- Founded
- GORO 1998
- CVM 1983
- Country
- GORO United States
- CVM United States
- Employees
- GORO N/A
- CVM N/A
- Industry
- GORO Precious Metals
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GORO Basic Materials
- CVM Health Care
- Exchange
- GORO Nasdaq
- CVM Nasdaq
- Market Cap
- GORO 43.4M
- CVM 40.1M
- IPO Year
- GORO N/A
- CVM 1987
- Fundamental
- Price
- GORO $0.39
- CVM $0.40
- Analyst Decision
- GORO Strong Buy
- CVM
- Analyst Count
- GORO 1
- CVM 0
- Target Price
- GORO $1.75
- CVM N/A
- AVG Volume (30 Days)
- GORO 2.4M
- CVM 1.2M
- Earning Date
- GORO 03-12-2025
- CVM 02-14-2025
- Dividend Yield
- GORO N/A
- CVM N/A
- EPS Growth
- GORO N/A
- CVM N/A
- EPS
- GORO N/A
- CVM N/A
- Revenue
- GORO $73,897,000.00
- CVM N/A
- Revenue This Year
- GORO N/A
- CVM N/A
- Revenue Next Year
- GORO $48.90
- CVM N/A
- P/E Ratio
- GORO N/A
- CVM N/A
- Revenue Growth
- GORO N/A
- CVM N/A
- 52 Week Low
- GORO $0.12
- CVM $0.33
- 52 Week High
- GORO $0.71
- CVM $2.50
- Technical
- Relative Strength Index (RSI)
- GORO 59.83
- CVM 45.54
- Support Level
- GORO $0.29
- CVM $0.39
- Resistance Level
- GORO $0.41
- CVM $0.68
- Average True Range (ATR)
- GORO 0.05
- CVM 0.06
- MACD
- GORO -0.00
- CVM 0.01
- Stochastic Oscillator
- GORO 83.67
- CVM 18.86
About GORO Gold Resource Corporation
Gold Resource Corp is a gold and silver producer, developer, and explorer with operations in Oaxaca, Mexico, and Nevada, USA. It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.